The Royal Marsden NHS Foundation Trust | Sutton - Oak Foundation Drug Development Unit

Sutton, Surrey SM2 5PT

2 studies enrolling now · 3 studies all time

What they study most

Advanced Metastatic Castration-resistant Prostate Cancer, MTAP-deleted Solid Tumors, Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression

Studies at this site

• First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors — Recruiting now
• A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) — Running, not enrolling